# ACCREDITATION COUNCIL FOR PHARMACY EDUCATION



Accreditation Action and Recommendations

JANUARY 19-21, 2017

Professional Program Leading to the Doctor of Pharmacy

UNIVERSITY OF PITTSBURGH

SCHOOL OF PHARMACY

PITTSBURGH, PENNSYLVANIA

### **Doctor of Pharmacy Program**

January 19-21, 2017

# I. Introduction

The Accreditation Council for Pharmacy Education (ACPE) Board of Directors reviewed the Doctor of Pharmacy program of the University of Pittsburgh, School of Pharmacy, for purposes of continued accreditation at its January 19-21, 2017, meeting. This review was based upon due consideration of the Evaluation Team Report from the on-site evaluation dated October 18-20, 2016, the School's self-study, and other communications received from the institution.

# II. Accreditation Action

Following discussion of the program, it was the decision of the Board that **accreditation of the Doctor of Pharmacy program be continued**. The professional program of the School and its accreditation status will be designated on ACPE's web site, <u>www.acpe-accredit.org</u>. Notice of the accreditation status of the program will also appear in the ACPE Report of the Proceedings, to be distributed during February 2017.

# III. Accreditation Terms and Conditions

A. <u>Accreditation Term</u> The accreditation term granted for the Doctor of Pharmacy program extends until <u>June 30, 2025</u>, which represents the customary eight-year cycle between self-studies. The academic year for the next currently scheduled review of the Doctor of Pharmacy program for purposes of continued accreditation is <u>2024-2025</u>. This schedule is contingent upon maintenance of the

presently observed quality during the stated accreditation term. The ACPE Board of Directors reserves the right to revise its accreditation action or to alter these dates based upon monitoring, such as written reports and/or focused on-site reviews as may be scheduled during the accreditation term stated above.

**B.** <u>Monitoring During the Accreditation Term</u> A <u>written interim report</u> should be submitted to the ACPE office no later than <u>April 1, 2017</u>, that addresses the issue identified in the Evaluation Team Report of October 18-20, 2016, and detailed below.

**C.** <u>Comments and Recommendations</u> This accreditation action was taken in recognition of the progress made since the last accreditation review and with confidence that existing School and programmatic needs will continue to be addressed in a timely manner and to the satisfaction of the ACPE Board of Directors. The Evaluation Team Report of October 18-20, 2016, presents important needs and developmental issues in keeping with Standards 2016. It should be noted that this Accreditation Action and Recommendations document and the Evaluation Team Report are companion documents and should be used together to guide the School's continuing developmental efforts.

The Board references specific issues below that should be included in the requested report and appends the *ACPE Guidelines for Interim Reports during the Accreditation Term* for guidance in preparing the submission.

# Summary of the Evaluation of All ACPE Standards

The evaluation of the program on each of the ACPE accreditation standards (Standards 2016) is noted below.

Standards	Compliant	Compliant with Monitoring	Partially Compliant	Non Compliant
SECTION I: EDUCATIONAL OUTCOMES				
1. Foundational Knowledge	$\boxtimes$			
2. Essentials for Practice and Care	$\boxtimes$			
3. Approach to Practice and Care	$\boxtimes$			
4. Personal and Professional Development	$\boxtimes$			
SECTION II: STRUCTURE AND PROCESS TO PROMOTE ACHIEVEMENT OF EDUCATIONAL OUTCOMES				
5. Eligibility and Reporting Requirements	$\boxtimes$			
6. College or School Vision, Mission, and Goals	$\boxtimes$			
7. Strategic Plan	$\boxtimes$			
8. Organization and Governance	$\boxtimes$			
9. Organizational Culture	$\boxtimes$			
10. Curriculum Design, Delivery, and Oversight	$\boxtimes$			
11. Interprofessional Education (IPE)	$\boxtimes$			
12. Pre-Advanced Pharmacy Practice Experiences (Pre-APPE) Curriculum	$\boxtimes$			
13. Advanced Pharmacy Practice Experiences (APPE) Curriculum	$\boxtimes$			
14. Student Services	$\boxtimes$			
15. Academic Environment	$\boxtimes$			
16. Admissions	$\boxtimes$			
17. Progression	$\boxtimes$			
18. Faculty and Staff – Quantitative Factors	$\boxtimes$			
19. Faculty and Staff – Qualitative Factors	$\boxtimes$			
20. Preceptors	$\boxtimes$			
21. Physical Facilities and Educational Resources		$\boxtimes$		
22. Practice Facilities	$\boxtimes$			
23. Financial Resources	$\boxtimes$			
SECTION III: ASSESSMENT OF STANDARDS AND KEY ELEMENTS				
24. Assessment Elements for Section I: Educational Outcomes	Х			
25. Assessment Elements for Section II: Structure and Process	Х			

# Monitoring requested by the ACPE Board for the Interim Report, by Standard:

# Standard No. 21: Physical Facilities and Educational Resources

A brief description of the status of financial support for the School's physical facility improvement/enhancement plans should be provided. This should include a brief description of the timeline (phasing) of implementation plans if available.

Additionally, ACPE may at any time during the awarded accreditation term request additional information. Once the requested issues have been addressed and the necessary information is submitted in the form of a requested interim report or onsite evaluation, review by the ACPE Board of Directors could result in the following outcomes:

- affirmation of the accreditation action, terms, and conditions with no additional reporting required;
- additional reporting could be requested to address issues that could not be addressed within the stated reporting timeframe, or to monitor issues requiring further attention; or
- additional on-site review by ACPE to permit observation of progress regarding issues requiring attention.

In accord with ACPE policy, if additional reporting and/or on-site review is not satisfactory in any area, the Board could then act to reduce a previously awarded accreditation term, award a probationary accreditation status, or take an adverse accreditation action (cf. Policies and Procedures for ACPE Accreditation of Professional Degree Programs, June 2016).

The Evaluation Team Report and the Accreditation Action and Recommendations are confidential documents and are considered to be the property of the institution. These documents will not be released to third parties without the authorization of the chief executive officer of the institution. Without such authorization, the sole information available to the public consists of that information contained in the <u>Directory and in the Report of Proceedings from the meeting at which the accreditation action was taken</u>. If the institution releases any portion of the Evaluation Team Report or the Accreditation Action and Recommendations, or releases any statement concerning such documents that ACPE believes requires public clarification or presents a misleading impression, ACPE may make an appropriate response or cause the release of such documents in their entirety.

Additionally, in accord with ACPE policy, the School is reminded that ACPE should be notified of any substantive change prior to its implementation to allow ACPE adequate time to consider the impact of the proposed change on programmatic quality. The ACPE substantive change policy provides details as to what constitutes such a change.

**D.** <u>Public Disclosure</u> It is expected that the accreditation status of the program will be fully disclosed. ACPE requires that all Colleges and Schools of Pharmacy it accredits to utilize the following language when referring to the accreditation status of the program in any publication, both in print and on the program's web site:

"University of Pittsburgh School of Pharmacy's Doctor of Pharmacy program is accredited by the Accreditation Council for Pharmacy Education, 135 South LaSalle Street, Suite 4100, Chicago, IL 60503, 312/664-3575; FAX 312/664-4652, web site <u>www.acpe-accredit.org</u>."

5

### ACCREDITATION COUNCIL FOR PHARMACY EDUCATION



### **INTERIM REPORT ACTION DOCUMENT**

JUNE 21-24, 2017

Professional Program Leading to the Doctor of Pharmacy Degree

UNIVERSITY OF PITTSBURGH

SCHOOL OF PHARMACY

PITTSBURGH, PENNSYLVANIA

**Current Accreditation Term:** Through June 30, 2025 (comprehensive review 2024-2025).

### Summary of Standards Addressed in the Interim Report, dated March 14, 2017:

Standard	Status Before Report	Status After Report
21: Physical Facilities and	Compliant with	Compliant with
Educational Resources	Monitoring	Monitoring

Administrative Changes: None Reported.

# Monitoring requested by the ACPE Board for the Interim Report, by Standard (with Board Comments in italics):

### Standard No. 21: Physical Facilities and Educational Resources

A brief description of the status of financial support for the School's physical facility improvement/enhancement plans should be provided.
This should include a brief description of the timeline (phasing) of implementation plans if available.

**Comments:** The Board notes that the School completed the Infrastructure and Programming Study to identify the scope of required infrastructure and program renovations which will occur over multiple phases. The Design Phase is expected to begin during 2017 and is expected to take one year to complete. Construction will take approximately three years. Funding for the renovation has been made a top priority in the Ten Year Capital Plan authorized in February 2017. The University has designated the project funding as "Definite" to the Board of Trustees.

### **Board Action:**

- The Board affirms accreditation of the PharmD program through <u>June 30,</u> <u>2025</u>.
- A written <u>interim report</u> should be provided no later than <u>April 1, 2019</u>, that addresses the following:
  - A **brief description** of the status of improvements/enhancements to the School's physical facilities.

### ACCREDITATION COUNCIL FOR PHARMACY EDUCATION



### **INTERIM REPORT ACTION DOCUMENT**

JUNE 19-22, 2019

Professional Program Leading to the Doctor of Pharmacy Degree

UNIVERSITY OF PITTSBURGH

SCHOOL OF PHARMACY

PITTSBURGH, PENNSYLVANIA

**Current Accreditation Term:** Through June 30, 2025 (comprehensive review 2024-2025).

### Summary of Standards Addressed in the Interim Report, dated March 28, 2019:

Standard	Status Before Report	Status After Report
21: Physical Facilities	Compliant with	Compliant with
and Educational	Monitoring	Monitoring
Resources	_	

Administrative Changes: None reported.

# Monitoring requested by the ACPE Board for the Interim Report, by Standard (with Board Comments in italics):

### Standard No. 21: Physical Facilities and Educational Resources

A <u>brief description</u> of the status of improvements/enhancements to the School's physical facilities.

**Comments:** The Board notes that the design plans for renovation of the School's portion of Salk Hall have been completed, funds have been approved by the University and a contractor has been selected. Faculty and staff have been moved to temporary space in preparation for the renovation. Construction will commence once approval is obtained from the Commonwealth Attorney General and Comptroller. Classes continue to be conducted in Salk Hall and construction is planned so as to minimize the impact on classroom activity.

### **Board Action:**

- □ The Board affirms accreditation of the PharmD program through <u>June 30.</u> <u>2025</u>.
- An interim report should be submitted by **October 1, 2020**, the includes:
  - A **<u>brief description</u>** of the status of improvements/enhancements to the School's physical facilities.



Patricia D. Kroboth, PhD, Dean Dr. Gordon J. Vanscoy Distinguished Service Professor School of Pharmacy 5607 Baum Blvd, Suite 303 Pittsburgh, PA 15206 412-624-2400 pkroboth@pitt.edu

September 30, 2020

J. Gregory Boyer, PhD, Assistant Executive Director of ACPE Director of Professional Degree Program Accreditation 190 S. LaSalle Street, Suite 2850 Chicago, IL 60603-3499 gboyer@acpe-accredit.org

RE: PittPharmacy Interim Report and Administrative Changes

Dear Greg,

It is my pleasure to provide you with this interim report as required according to the Interim Report Action Document (IRAD) dated June 19-22, 2019. The report regarding Standard 21 (Physical Facilities) is due on October 1, 2020. Our report is preceded by statements from the IRAD for the sake of clarity.

#### **IRAD Statement**

# Monitoring requested by the ACPE Board for the Interim Report, by Standard (*with Board Comments in italics*): Standard No. 21: Physical Facilities and Educational Resources

**Comments:** The Board notes that the design plans for renovation of the School's portion of Salk Hall have been completed, funds have been approved by the University and a contractor has been selected. Faculty and staff have been moved to temporary space in preparation for the renovation. Construction will commence once approval is obtained from the Commonwealth Attorney General and Comptroller. Classes continue to be conducted in Salk Hall and construction is planned so as to minimize the impact on classroom activity.

#### **Board Action:**

- □ The Board affirms accreditation of the PharmD program through June 30, 2025.
- An interim report should be submitted by **October 1, 2020**, the includes:

• A **brief description** of the status of improvements/enhancements to the School's physical facilities.

G. Boyer, PhD PittPharmacy Interim Report and Administrative Changes September 30, 2020 Page 2

### **INTERIM REPORT**

- Construction started May 13, 2019, which was later than expected. Due to COVID-19, construction halted March 17, 2020, further delaying the completion date of the renovations. The project restarted on June 8, 2020. Since the restart, construction has progressed at a relatively rapid pace.
- The new projected completion date for Salk Hall renovations is August 2021.
- Access to classrooms and Student Services in Salk Hall has been and will remain uninterrupted during the fall and spring academic terms.

### **ADMINISTRATIVE CHANGES**

Anantha Shekhar, MD, PhD assumed the responsibilities as Senior Vice Chancellor Health Sciences and Dean, School of Medicine on May 1, 2020, taking over for Arthur S. Levine, MD.

Several associate deans in the School of Pharmacy vacated their positions to take on responsibilities either external or internal to the University of Pittsburgh. These changes provide new opportunities for leadership and leadership development.

Randall B. Smith, PhD, Senior Associate Dean will have oversight for Graduate and Postdoctoral Programs, a role being vacated by Samuel Poloyac, PharmD, PhD, Associate Dean, who will become the Dean University of Texas at Austin in October 2020.

Dr. Smith served for a year as Director of Experiential Learning and has now taken on oversight of the Office of Experiential Learning with the departure of Susan Meyer, PhD, Associate Dean for Education, who is now focusing all but 10 percent of her time at the Office of the Provost as Director of Interprofessional Education. Our Experiential Learning Team, including the Director, remains strong and creative.

- Amy Seybert, PharmD will have general oversight of the PharmD program, which has a number of highly experienced and capable leaders, including Assistant Dean Denise Howrie as Curriculum Committee Chair; Melissa McGivney, Associate Dean for Community Partnerships; Director of Assessment Neal Benedict; and Co-Curriculum Co-Directors Karen Pater and Kris Schonder.
- Thomas Nolin, PharmD, PhD performed superbly as Interim Senior Associate Dean while Dr. Smith was away last summer. Dr. Nolin has assumed responsibilities for research oversight and is in the process of being officially named Associate Dean for Research.
- Mario Browne, MPH, EdD Candidate, is in the final phases of being appointed as the inaugural Associate Dean for Equity, Inclusion and Justice.
- Gordon Vanscoy, PharmD, MBA, Associate Dean for Business Innovation stepped away from his part-time role at Pitt to focus effort on his relatively new \$1 billion business. That position will not be filled, though the functions are being assumed by Bridget Regan, PharmD, Director of the Masters of Pharmacy Business Administration and John Riley, MBA.

G. Boyer, PhD PittPharmacy Interim Report and Administrative Changes September 30, 2020 Page 3

A new programmatic leadership structure will be defined by June 30, 2021. Until then, I will be hosting a Leadership Development Series for a select group of faculty who will participate in Leadership Team meetings and in making key decisions.

Please do not hesitate to call with any questions.

May you remain healthy!

atricia Froboth

Patricia D. Kroboth

We at PittPharmacy have realized the challenges of systemic racism, bias and structural inequality.

We stand with Black, Indigenous, and People of Color against racism. We take an anti-racist stance. We must reflect on our own beliefs, words, actions, and interactions. We MUST do better. We WILL do better.

We are taking immediate steps. We are listening. We are learning. We are taking action to assure a PittPharmacy community that is truly equitable and just.